Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > THTX 3,25$

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Feb 01, 2022 4:40pm

172 Views

Post# 34386921

RE:THTX 3,25$

These moves up are almost as surprising as moves down.

For 6 months it tightly followed XBI. Last 2 weeks it's been positive while XBI has mostly been negative expect last few days where both are positive. If you think XBI in the background baseline then THTX has been doing well in 2022. None of it feels really positive but it seems to be doing OK.